Short answer
GYRE THERAPEUTICS, INC. (GYRE) filed an 8-K current report with the SEC on May 7, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q1 2026 financial results for the three months ended March 31, 2026.
GYRE THERAPEUTICS, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q1 2026 financial results for the three months ended March 31, 2026
- Press release issued May 7, 2026 and furnished as Exhibit 99.1
- Investors should review Exhibit 99.1 for revenue, expenses, cash position, and management commentary
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other GYRE THERAPEUTICS, INC. 8-K filings
Get the next GYRE 8-K as it lands
Follow GYRE for push alerts, or ask the research agent what this filing means.